Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
Status:
Completed
Trial end date:
2021-04-16
Target enrollment:
Participant gender:
Summary
Phase IIb study to evaluate the efficacy and the safety of 3 dose-levels of ABX464,
administered daily in patients with moderate to severe Ulcerative Colitis.